Board OF DIRECTORS
Anand Tharmaratnam
Chairman
Anand Tharmaratnam
Chairman
Anand brings over 20 years of experience in global drug development and the CRO industry. He was previously President Asia Pacific at IQVIA. Anand is a medical doctor by training and graduated from the University College London, UK and trained in Anaesthesia and Critical Care
Joel Thickins
Board Member
Joel Thickins
Board Member
Joel is a Partner at TPG Capital and leads the firm’s investment program in the ANZ region as Head of Australia and New Zealand. Joel also currently sits on the Board of Inghams Group Limited and has served on the Boards of Accolade Wines, Gerard Lighting, Blue Star Print Group and Centric Wealth.
Before joining TPG, Joel was a Director at CHAMP Private Equity; where he was responsible for the company’s activities in the industrial, agricultural services and consumer markets. Prior to CHAMP, Joel was a Vice President at Dyno Nobel Limited, where he led acquisitions in China, Europe and North America; and held strategic and operational positions at Boral Limited in the United States. Joel is a Guest Lecturer on Private Equity at Melbourne Business School.
Dr. Fred Cohen
Board Member
Dr. Fred Cohen
Board Member
Fred Cohen is a Senior Advisor to TPG and was a Partner and co-founder of TPG Biotechnology. Fred has served on the Board of several biotech and pharmaceutical organizations including Biocryst (BCRX), CareDx (CDNA), […] and is a co-founder of Sweetwater Spectrum, a non-profit autism support organization.
Vincent Wong
Board Member
Vincent Wong
Board Member
Vincent Wong is a Managing Director with TPG Capital and is based in Melbourne, where he works in TPG’s Australian team. Prior to joining TPG in 2011, Vincent served in the Investment Banking Department at Goldman, Sachs & Co. Vincent graduated from The University of Melbourne with BCommerce and BLaws (Honors).
Lydia Cai
Board Member
Lydia Cai
Board Member
Lydia Cai is a Managing Director with TPG Capital Asia based in Beijing and leads TPG’s healthcare investments in the Greater China area. Prior to joining TPG in 2011, Lydia was an Associate at HAO Capital, a China-focused early stage private equity fund focusing on growth-stage healthcare investments.
John Moller
Chief Executive Officer
John Moller
Chief Executive Officer
John joined Novotech in January 2014 to lead the development of Novotech’s Asia operations. Prior to Novotech John was Managing Director of IVF Australia and Queensland Fertility Group and sat on the Board of the parent company Virtus Health. John is a medical doctor by training.
Veronica Holloway
Chief Legal and Compliance Officer
Veronica Holloway
Chief Legal and Compliance Officer
Veronica joined Novotech in May 2014 to formalise the legal function at Novotech. Prior to Novotech, Veronica held roles as Senior Legal Counsel at EY, Senior Solicitor at Clayton Utz and General Counsel (on secondment) at Novartis Pharmaceuticals Australia Pty Limited. Veronica holds a BA/LLB/LLM.
Executive Management
John Moller
Chief Executive Officer
John Moller
Chief Executive Officer
John joined Novotech in January 2014 to lead the development of Novotech’s Asia operations. Prior to Novotech John was Managing Director of IVF Australia and Queensland Fertility Group and sat on the Board of the parent company Virtus Health. John is a medical doctor by training.
Michael stibilj
Chief Operating Officer
Michael stibilj
Chief Operating Officer
Michael has 25 years of experience in the CRO Industry. Prior to joining Novotech in 2017, Michael spent 15 years building and leading operations across Asia for Quintiles/IQVIA, and was senior advisor for TPG Capital.
Zidong Zhang
Group Chief Finance Officer
Zidong Zhang
Group Chief Finance Officer
Zidong Zhang is responsible for all aspects of financial management to support the growth of Novotech across Asia. Prior to joining Novotech, Dr. Zhang was CFO at Henlius Biotech, a Hong Kong-listed global biopharmaceutical company based in Shanghai, where he built and managed the finance team and played an integral role in the company’s initial public offering in 2019. Prior to that, Dr. Zhang was an equity research analyst at UBS in New York, where he covered the Major and Specialty Pharmaceutical Sector.
Barry Murphy
Chief Commercial Officer
Barry Murphy
Chief Commercial Officer
Barry joined in July 2014 to lead the growth of Novotech’s Business Development team. Barry started his career as a pharmacist having graduated from Trinity College Dublin. He began his clinical research career with ICON and worked in both Dublin and Sydney.
Andy Liu
Head of China
Andy Liu
Head of China
Andy worked at Covance, Inc., a global CRO, for more than 10 years in a number of executive positions. Most recently, he was General Manager of Covance's Central Laboratory Service, Asia Pacific, where he led a large multi-functional team of around 500 employees across multiple sites in APAC. Andy holds an MBA from the Booth School of Business at the University of Chicago, an MS in Electrical Engineering from the Rose-Hulman Institute of Technology, and a BS in Electrical Engineering from Tsinghua University.
Veronica Holloway
Chief Legal and Compliance Officer
Veronica Holloway
Chief Legal and Compliance Officer
Veronica joined Novotech in May 2014 to formalise the legal function at Novotech. Prior to Novotech, Veronica held roles as Senior Legal Counsel at EY, Senior Solicitor at Clayton Utz and General Counsel (on secondment) at Novartis Pharmaceuticals Australia Pty Limited. Veronica holds a BA/LLB/LLM.
Angela Edwardson
Chief People Officer
Angela Edwardson
Chief People Officer
Angela joined Novotech in November 2015 and is responsible for Novotech's Human Resources operations including strategy, organisational development, remuneration & reward and workplace health and safety. Angela is passionate about delivering Novotech's vision of being the leading CRO in the Asia Pacific region.